The alteration and significance of serum concentrations of FSTL1 after PCI in patients with acute coronary syndrome

Abstract

Objective To investigate the value of follistatin-like 1(FSTL1)in acute coronary syndrome patients treated with percutaneous coronary intervention(PCI). Methods 100 patients with ACS were included in department of Cardiovascular medicine, Lianyugang Second People′s Hospital from January 2015 to December 2016.26 patients were unstable angina pectoris, 45 patients were non-ST-segment elevation myocardial infarction, 29 patients were ST segment elevation myocardial infarction.All patients were divided into PCI group(n=50)and drug group(n=50)according to the therapeutic method.Patients in PCI group were performed PCI in 12 h after diagnosing denfinitively, and were adiministrated drug thepapy of dual antiplatelet, anticoagulation, vasoactive drugs, anti-tensor coronary artery, nutrition myocardial and anti-hyperlipidemia.Patients in drug group were adiministrated drug thepapy of dual antiplatelet, anticoagulation, vasoactive drugs, anti-tensor coronary artery, nutrition myocardial and anti-hyperlipidemia.Enzyme linked immunosorbent assay measured the level of FSTL1 at prior treatment, 24 h after treatment, 7 d after treatment.All patients were followed up for 6 months, and the incidence of major adverse cardiac events(MACE)was observed. Results The serum levels of FSTL1 in PCI group at 24 h, 7d after treatment were significantly lower than those before treatment(P<0.05). The level of serum FSTL1 in the drug group at 7 d[(8.35±3.26)ng/ml]after treatment was significantly lower than those before treatment[(12.05±1.83)ng/ml](P<0.05). The serum levels of FSTL1 in PCI group at 24 h[(7.05±3.58)ng/ml]and 7 d[(4.68±1.63)ng/ml]after treatment were lower than those in drug group[(12.67±0.52)ng/ml、(8.35±3.26)ng/ml](P<0.05). Followed up for 6 months, one patient occured MACE in PCI group, seven patients occured MACE in drug group(P<0.05). The FSTL1 of no MACE patients at pre-treatment[(12.05±2.21)ng/ml], 24 h[(9.11±1.45)ng/ml]and 7 d[(4.95±2.27)ng/ml]after treatment were lower than those of MACE patients[(20.11±4.15)ng/ml、(15.52±3.65)ng/ml、(9.92±2.13)ng/ml](P<0.05). Conclusion The level of FSTL1 in ACS patients and the incidence of MACE both decreases significantly.The examination of serum FSTL1 level in ACS patients has clinical value for evaluating the therapeutic effect and prognosis. Key words: Acute coronary syndrome; Percutaneous coronary intervention; Follistatin-like protein 1; Major cardiovascular events